Angelo Delmonte

Meldola, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 118 publications

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

Journal: The oncologist

Published: February 11, 2026

Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional - prospective study to inform referral for germline testing.

Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional - prospective study to inform referral for germline testing.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 18, 2026

Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer.

Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer.

Journal: Biology

Published: December 30, 2025

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.

Journal: Future oncology (London, England)

Published: December 18, 2025

Real-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study.

Real-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study.

Journal: Cancers

Published: December 15, 2025

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.

Journal: Targeted oncology

Published: September 02, 2025

Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial.

Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial.

Journal: Cancer treatment and research communications

Published: July 22, 2025

Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial.

Crizotinib in Patients With ROS1-Positive NSCLC With or Without Brain Metastases: Post Hoc Analysis of Phase II METROS Trial.

Journal: JTO clinical and research reports

Published: June 03, 2025

Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study.

Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study.

Journal: ESMO open

Published: May 02, 2025

Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study.

Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study.

Journal: ESMO open

Published: March 05, 2025

Clinicopathological Features of Non-Small Cell Lung Carcinoma with NRAS Mutation.

Clinicopathological Features of Non-Small Cell Lung Carcinoma with NRAS Mutation.

Journal: Journal of personalized medicine

Published: March 02, 2025

The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results.

The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results.

Journal: Clinical lung cancer

Published: January 27, 2025

Showing 1-12 of 118

Last Updated: 09/26/2026